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This study investigated the immunohistochemical 
expression of the cancer testis antigen SSX in 
prostate cancer. SSX expression, with varying 
staining intensities, was observed in 83% of can-
cer samples. Substantial heterogeneity of expres-
sion was observed within individual samples. 
SSX expression was significantly higher in 
Gleason score 7 than in Gleason score 6 cancer 
(p=0.008). Tumours demonstrating capsular inva-
sion had higher SSX expression than did tumours 
without capsular invasion (p=0.005). SSX expres-
sion did not correlate significantly with prostate-
specific antigen level or tumour size. Further 
studies are needed to investigate SSX expression 
in prostate cancer and its potential implications 




U ovom radu istraživali smo imunohistokemijsku 
ekspresiju karcinom testis antigena SSX u karci-
nomu prostate. SSX ekspresija različitog in-
tenziteta je pokazana u 83% uzoraka karcinoma. 
Pokazana je također i značajna heterogenost ek-
spresije unutar individaulnih uzoraka. SSX ek-
spresija je bila značajno više u Gleason zbroju 7, 
nego u Gleason zbroju 6 karcinoma prostate 
(p=0.008). Tumori koji su zahvatili kapsulu pros-
tate imali su također značajniju SSX ekspresiju 
nego tumori koji nisu zahvatili kapsulu (p=0.005). 
SSX ekspresija nije korelirala značajno s vrijed-
nostima prostata-specifičnog antigena ili 
veličinom tumora. Daljnje studije su potrebna da 
bi se istražila ekpresija SSX antigena u karcinomu 
prostate s potencijalnim implikacijama i na dijag-




SSX is one of the cancer testis antigens (CTA), a 
group of proteins expressed in a limited number 
of healthy tissues and in a large variety of tu-
mours of unrelated histological origins /1/. CTA 
have been shown to induce humoral and cellular 
immune responses. Therefore, a number of them 
are under evaluation as vaccines in active specific 
tumour immunotherapy /2/, /3/, /4/. Among the 
CTA, MAGE-A3/4, LAGE-1, NY-ESO-1 and SSX 
have been shown to be expressed in patients with 
prostate cancer /5/, /6/, /7/. Thus, immunotherapy 
for prostate cancer targeting one or a combination 
of these antigens may be possible. The generation 
of specific monoclonal antibodies (mAb) has per-
mitted the identification of CTA in tumour tis-
sues. The expression of these antigens is frequent-
ly focal /8/, making it necessary to explore rela-
tively large portions of tumour tissues in order to 
obtain precise data. In this study, we used im-
munohistochemistry (IHC) to investigate the ex-
pression of SSX in tissue sections of the whole 
organ and correlated SSX expression with pros-
tate-specific antigen (PSA) levels and histological 
tumour features important for determining prog-
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Prostate specimens from 53 patients (mean age 66, 
range 55-76 years) who underwent radical prosta-
tectomy at the Urology Clinic of the Zagreb Clini-
cal Hospital Center from 2005 to 2007 were as-
sessed in this study. The patients’ PSA values, 
determined before surgery, ranged from 0.2 to 
28.6 ng/mL (mean 9.05 ng/mL). In all patients, 
before surgery, the existence of distant metastases 
was ruled out by preoperative diagnostic testing, 
including complete laboratory tests, thorax radi-
ography, computed tomography of the pelvis, 
bone scintigraphy if necessary, and, depending on 
the results of the latter, targeted bone radiog-
raphy. The existence of metastases in regional 
lymph nodes was ruled out by immediate in-
traoperative and subsequent histopathological 
analysis of tissues embedded in paraffin blocks. In 
the patients studied, the clinical disease stages 
ranged from T1 to T3N0M0 /9/. 
 
Immunohistochemistry 
Entire prostates, surgically removed together with 
the base of the seminal vesicles, were formalin-
fixed and embedded in paraffin blocks that were 
cut into 4 - 5µm sections and HE stained in order 
to determine a histopathological diagnosis. 
Gleason grade and score were determined in a 
standard manner /10/. One patient (2%) had 
Gleason score 5 cancer, 19 (36%) had Gleason 
score 6 cancer, 31 (58%) had Gleason score 7 can-
cer, and 2 (4%) had Gleason score 8 cancer. The 
mAb anti-SSX (E3AS), a gift from Dr. Diederik de 
Bruijnwas (University Medical Center Nijmegen, 
Netherlands) was used for immunohistochemical 
staining /11/. Tissue sections of 3-5 µm thickness 
were cut from paraffin-embedded tissue blocks 
and placed on object slides (Menzel-Glaser, Ger-
many). Slides with tissue sections were incubated 
for 20 minutes at 60°C. Sections were then depar-
affined and pretreated for 3x5 minutes in 10 
mmol/L EDTA pH 9.0 in a microwave oven at 800 
W power. Subsequently, tissue slides were 
washed with PBS-buffer (pH 7.2) and endogenous 
peroxidase activity was blocked by a 5-minute 
treatment with H2O2 (Dako-No.S2023). Slides were 
then washed with PBS-buffer and incubated for 30 
minutes with SSX2 mAb, E3AS diluted at 1:200 at 
room temperature. After a wash in PBS-buffer, the 
secondary biotinylated antibody (Dako-
No.K0690) was added for a 30-minute incubation. 
Slides were then washed with PBS-buffer and 
treated with streptoavidin-horseradish peroxidase 
(Dako-No.K0690) for 30 minutes. Tissue sections 
were washed once more in PBS-buffer and then 
Chromogen (Dako-No.K3468) was added for 5 
minutes. Slides were washed in distilled water, 
stained with hemalaun (Dako-No.S2020) for 1 
minute, washed with water, dehydrated with 
alcohol (96%), cleared with xylen and mechanical-
ly covered. Testes tissues expressing SSX were 
used as a positive control throughout the study, 
whereas normal prostatic tissues and unstained 
tumour cells served as a negative control. IHC 
staining results were semiquantitatively ex-
pressed as follows: 1) negative response (-): no 
staining in tumour cells; 2) weak positive re-
sponse (+): up to 10% of tumour cells positive; 3) 
moderate positive response (++): 11 – 50% of tu-
mour cells positive; 4) strong positive response 
(+++): over 50% of tumour cells positive. 
 
Statistical analysis 
Statistical analysis was carried out using StatSoft 
Statistica data analysis software, version 6.1. The 
chi-square test and Spearman rank correlation 
were used throughout this work, and differences 




Expression of SSX, as detectable by E3AS mAb 
staining, was observed in 44/53 (83%) of carcino-
ma samples, with varying staining results. In all 
cases IHC staining was only detectable in the cy-
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Figure 1. IHC expression of SSX in cytoplasm of prostate tumour cells (x400). 
Substantial heterogeneity could be observed in 
individual tissue samples, with areas of strong 
positivities co-existing with SSX-negative areas. 
However, positivities involving more than 50% of 
tumour cells (+++) were observed in 18/53 (34%) 
cases (Table 1). 
 
Table 1. Distribution of SSX expression levels in cancerous prostatic tissue amongst all patients and correla-
tion of SSX expression with Gleason score and prostatic capsule status. Data represent numbers and (in pa-
rentheses) percentages of patients. The data for Gleason scores 5 and 8 are not shown because the number of 
patients with these scores (3) was too small for statistical analysis. P values indicate significance levels for 
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When comparing Gleason score and SSX expres-
sion, the chi-square test showed that patients with 
Gleason score 7 had in most cases higher levels of 
SSX expression than did patients with Gleason 
score 6 (p=0.008). Tumours that had infiltrated the 
prostatic capsule had in most cases higher levels 
of SSX expression than did those that had not 
infiltrated the capsule (p=0.005) (Table 1). SSX 
expression did not correlate significantly with 
PSA level (p=0.13) or with tumour size (range 0.5-
4 cm, mean 2.4 cm) (p=0.22). The number of pa-
tients with seminal vesicle invasion (6) was too 
small for adequate statistical analysis. In some 
samples, where tumour tissue coexisted with are-
as of benign prostatic hyperplasia (BPH), SSX 
expression was also detectable in some of the 
areas of BPH, although staining was less intense 
in these areas and involved low numbers of cells.  
 
Discussion and conclusion 
It has been shown that SSX is a prostate cancer 
antigen and that it can be immunologically recog-
nized in patients with prostate cancer /12/. Prov-
ing that SSX is present in prostate cancer samples 
and that it can be recognized by immune system 
provides a basis for possible immunotherapy 
using vaccination with this antigen, alone or in 
combination with other CTA. Expression of CTA 
is often focal, and within a single tissue sample, 
areas with strong positivities may co-exist with 
CTA-negative areas. In prior studies, we showed 
that this was the case for MAGE-A1, MAGE-A3/4 
and NY-ESO-1 /13/ expression in prostate cancer, 
and in the present study, we have shown that is 
also the case for SSX expression in prostate cancer. 
Performing staining of sections of the whole ex-
cised prostate allowed us to carry out a detailed 
evaluation of SSX expression at the protein level, 
together with nearby areas of normal and BPH 
tissue. In contrast, studies limited to bioptic mate-
rials or tissue microarrays /14/  might result in 
underestimation of CTA expression. We found 
that cancers with higher Gleason scores had high-
er levels of SSX expression; we also found that 
SSX expression was higher in prostate cancers that 
invaded the prostate capsule. Recently, it has been 
demonstrated that expression of SSX—like the 
expression of other members of the CTA group—
is elevated in metastatic disease /15/, /16/. The 
latter finding, together with our results, leads us 
to the conclusion that SSX expression is higher in 
more advanced or more aggressive forms of pros-
tate cancer. This conclusion is in accordance with 
previous studies that have shown CTA expression 
to be higher in less differentiated, higher-grade 
tumours (e.g., in high-grade bladder cancer) /17/. 
At our institution radical prostatectomy is usually 
performed only in patients with a Gleason score 
of 7 or less because of the higher likelihood of 
organ-confined disease; therefore, we only had 
limited access to tumours with higher Gleason 
scores. Although our study did include some pa-
tients with Gleason score 8, the number was too 
small for adequate statistical analysis. Bioptic 
samples of tumours with Gleason scores 8-10 
were excluded because of the known heterogenei-
ty of CTA expression. In our study, neither PSA 
level nor tumour size correlated significantly with 
SSX expression.  A PSA value > 4 ng/mL is suspi-
cious for prostate cancer, but the PSA level can be 
influenced not only by cancer but by other factors 
such as inflammation and BPH. Furthermore, it 
has been shown that patients with a PSA level of < 
4 ng/mL, which is considered to be “normal,” can 
have aggressive, high-grade forms of prostate 
cancer /18/. SSX expression has also been detected 
in BPH in the presence or absence of neoplastic 
transformation, although in low numbers of cells. 
Sugita et al. /19/ have reported expression  of the 
NY-ESO-1 gene, a member of the CTA group, in 
42% of breast cancers together with weak but 
detectable expression in as much as 68% of benign 
breast tissue. They suggested that benign lesions 
might actually represent, at least in part, early 
stages of malignant transformation. The eventual 
pre-cancerous nature of SSX-positive cells in BPH 
deserves careful study. SSX is a recognized pros-
tate cancer tumour antigen, although weak SSX 
expression has also been detected in some sam-
ples of BPH. We found that SSX expression in 
prostate cancer increased with higher Gleason 
scores and with the presence of capsular inva-
sion—i.e., in more aggressive forms of the disease.  
Further studies are needed to investigate SSX 
expression in prostate cancer (especially in more 
advanced forms of the disease) and its potential 
implications regarding both diagnosis and immu-
notherapy.  
 
   
References 
 
/1/ Zendman AJ, Ruiter DJ, Van Muijen GN. Can-
cer/testis-associated genes: identification, expression 
profile, and putative function. J Cell Physiol 
2003;194:272-88 
Tvrtko Hudolin, Ahmad El-Saleh, Ljiljana Hlupić, Željko Kaštelan: TUMOR ANTIGENS IN PROSTATE CANCER 
Informatol.  50, 2017., 1-2, 58-62 




Figure 1. IHC expression of SSX in cytoplasm of prostate tumour cells (x400). 
Substantial heterogeneity could be observed in 
individual tissue samples, with areas of strong 
positivities co-existing with SSX-negative areas. 
However, positivities involving more than 50% of 
tumour cells (+++) were observed in 18/53 (34%) 
cases (Table 1). 
 
Table 1. Distribution of SSX expression levels in cancerous prostatic tissue amongst all patients and correla-
tion of SSX expression with Gleason score and prostatic capsule status. Data represent numbers and (in pa-
rentheses) percentages of patients. The data for Gleason scores 5 and 8 are not shown because the number of 
patients with these scores (3) was too small for statistical analysis. P values indicate significance levels for 




































































                  p=0.005 
 
62
Tvrtko Hudolin, Ahmad El-Saleh, Ljiljana Hlupić, Željko Kaštelan: TUMOR ANTIGENS IN PROSTATE CANCER 
Informatol.  50, 2017., 1-2, 58-62 
ISSN 1330-0067                                                                                                                            Coden: IORME7 
 
  
/2/ Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit 
WH, Keilholz U et al. Immunisation of metastatic 
cancer patients with MAGE-3 protein combined 
with adjuvant SBAS-2: a clinical report. Eur J Cancer 
2003;39:70-7 
/3/  Thurner B, Haendle I, Röder C, Dieckmann D, 
Keikavoussi P, Jonuleit H et al. Vaccination with 
mage-3A1 peptide-pulsed mature, monocyte-
derived dendritic cells expands specific cytotoxic T 
cells and induces regression of some metastases in 
advanced stage IV melanoma. J Exp Med 
1999;190:1669-78 
/4/ Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, 
Dummer R et al. Vaccination of melanoma patients 
with peptide- or tumor lysate-pulsed dendritic cells. 
Nat Med 1998;4:328-32 
/5/  Hudolin T, Juretic A, Spagnoli GC, Pasini J, Bandic 
D, Heberer M et al. Immunohistochemical expres-
sion of tumor antigens MAGE-A1, MAGE-A3/4 and 
NY-ESO-1 in cancerous and benign prostatic tissue. 
Prostate 2006;66:13-8  
/6/  Lethé B, Lucas S, Michaux L, De Smet C, Godelaine 
D, Serrano A et al. LAGE-1, a new gene with tumor 
specificity. Int J Cancer 1998;76:903-8  
/7/ Dubovsky JA, McNeel DG. Inducible expression of a 
prostate cancer-testis antigen, SSX-2, following 
treatment with a DNA methylation inhibitor. Pros-
tate 2007;67:1781-90 
/8/ Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. 
Cancer/testis tumour-associated antigens:  im-
munohistochemical detection with monoclonal an-
tibodies. Lancet Oncol 2003;4:104-9 
/9/ Greene FL, Page DL, Fleming ID, editors. Prostate. 
AJCC Cancer Staging Manual, 6th ed. New York: 
Springer Verlag; 2002, 309 p. 
/10/ Eble JN, Sauter G, Epstein JI, Sesterhenn IA, edi-
tors. WHO Pathology and Genetics of Tumours of 
the Urinary System and Male Genital Organs. Lyon: 
IARC Press; 2004, 179 p.  
/11/ dos Santos NR, Torensma R, de Vries TJ, Schreurs 
MW, de Bruijn DR, Kater-Baats E et al. Heterogene-
ous expression of the SSX cancer/testis antigens in 
human melanoma lesions and cell lines. Cancer Res 
2000;60:1654-62 
/12/ Dubovsky JA, McNeel DG. Inducible expression of 
a prostate cancer-testis antigen, SSX-2, following 
treatment with a DNA methylation inhibitor. Pros-
tate 2007;67:1781-90 
/13/ Hudolin T, Juretic A, Spagnoli GC, Pasini J, Bandic 
D, Heberer M et al. Immunohistochemical expres-
sion of tumor antigens MAGE-A1, MAGE-A3/4 and 
NY-ESO-1 in cancerous and benign prostatic tissue. 
Prostate 2006;66:13-8  
/14/ Dubovsky JA, McNeel DG. Inducible expression of 
a prostate cancer-testis antigen, SSX-2, following 
treatment with a DNA methylation inhibitor. Pros-
tate 2007;67:1781-90 
/15/ Ibidem 
/16/ Nakada T, Noguchi Y, Satoh S, Ono T, Saika T, 
Kurashige T, et al. NY-ESO-1 mRNA expression and 
immunogenicity in advanced prostate cancer. Can-
cer Immun 2003;31:3-10 
/17/ Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, 
Jungbluth A et al. NY-ESO-1 expression and immu-
nogenicity associated with transitional cell carcino-
ma: correlation with tumor grade. Cancer Res 
2001;61:4671-4 
/18/ Thompson IM, Pauler DK, Goodman PJ, Tangen 
CM, Lucia MS, Parnes HL et al. Prevalence of pros-
tate cancer among men with a prostate-specific an-
tigen level < or =4.0 ng per milliliter. N Engl J Med 
2004;350:2239-46 
/19/ Sugita Y, Wada H, Fujita S, Nakata T, Sato S, No-
guchi Y et al. NY-ESO-1 expression and immuno-
genicity in malignant and benign breast tumors. 
Cancer Res 2004;64:2199-204 
  
